SML0042
Lazabemide hydrate
≥97% (HPLC)
Synonym(s):
N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide hydrate, Ro 19-6327 hydrate
Sign Into View Organizational & Contract Pricing
Select a Size
10 MG
$67.90
50 MG
$387.00
$67.90
Check Cart for Availability
All Photos(1)
Select a Size
Change View
10 MG
$67.90
50 MG
$387.00
About This Item
Empirical Formula (Hill Notation):
C8H10ClN3O · xH2O
CAS Number:
Molecular Weight:
199.64 (anhydrous basis)
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
$67.90
Check Cart for Availability
Recommended Products
Quality Level
assay
≥97% (HPLC)
form
powder
storage condition
desiccated
color
white to tan
solubility
DMSO: ≥22 mg/mL
originator
Roche
storage temp.
room temp
SMILES string
O.NCCNC(=O)c1ccc(Cl)cn1
InChI
1S/C8H10ClN3O.H2O/c9-6-1-2-7(12-5-6)8(13)11-4-3-10;/h1-2,5H,3-4,10H2,(H,11,13);1H2
InChI key
JYWYNPKXSLPWGV-UHFFFAOYSA-N
Application
Lazabemide hydrate may be used in cell signaling studies.
Biochem/physiol Actions
Lazabemide is a selective and reversible monoamine oxidase B (MAO-B) inhibitor and Anti-Parkinson. Also it inhibits monoamine uptake at high concentrations (IC50 values are 86, 123 and > 500 μM for noradrenalin, serotonin and dopamine uptake respectively).
Lazabemide is effective in treatment of Alzheimer′s disease[1] and in combination with nicotine replacement therapy aids in smoking cessation.[2]
Selective MAO-B inhibitor; Antiparkinson
Features and Benefits
This compound is featured on the Dopamine and Norepinephrine Metabolism and Histamine Synthesis and Metabolism pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Don't see the Right Version?
If you require a particular version, you can look up a specific certificate by the Lot or Batch number.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yuji Kitaichi et al.
European journal of pharmacology, 532(3), 236-245 (2006-02-21)
We investigated the effects of clorgyline [a selective MAO (monoamine oxidase inhibitor)-A inhibitor] and lazabemide (a selective MAO-B inhibitor) on extracellular serotonin, dopamine and noradrenaline concentrations in the medial prefrontal cortex after 1-week treatment with subchronic 0.2% or 0.05% Li2CO3
A D Macleod et al.
The Cochrane database of systematic reviews, (3)(3), CD004898-CD004898 (2005-07-22)
It has been postulated that monoamine oxidase B (MAO-B) inhibitors alter disease progression in Parkinson's disease (PD). Clinical trials have produced conflicting results. To assess the evidence from randomized controlled trials for the effectiveness and safety of long-term use of
Violetta Klimek et al.
Journal of psychiatric research, 37(5), 387-397 (2003-07-10)
Neurochemical imbalance between noradrenergic and serotonergic systems has been postulated to underlie the pathophysiology of psychiatric illnesses involving mood disorders. The present study was designed to examined the possibility that serotonergic innervation of the locus coeruleus (LC) is abnormal in
J Jolkkonen et al.
Pharmacology & toxicology, 87(5), 242-245 (2000-12-29)
The present study investigated the effect of postischaemic infusion of an irreversible monoamine oxidase B (MAO-B) inhibitor, l-deprenyl, an equipotent dose of a reversible MAO-B inhibitor, lazabemide, or 0.9% NaCl on infarct volumes following focal cerebral ischaemia in rats. The
D H Fitzgerald et al.
Journal of neural transmission (Vienna, Austria : 1996), 109(3), 251-265 (2002-04-17)
The specific activity and kinetic behaviour of semicarbazide-sensitive amine oxidase (EC 1.4.3.6; SSAO) towards benzylamine, in the rat heart, is affected by in vivo treatment with the non-selective monoamine oxidase (MAO) inhibitor tranylcypromine, but not by the selective MAO-A and
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
